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Abstract
Continuous renal replacement therapy (CRRT) is considered as an effective modality for renal replacement therapy in
hemodynamically unstable patients within intensive care units (ICUs). However, the role of heparin anticoagulation, which is
used to maintain circuit patency, is equivocal due to the risk of bleeding and morbidity. Among various alternative
anticoagulants, nafamostat mesilate has been shown to be an effective anticoagulant in patients prone to bleeding. Hence,
we conducted a prospective, randomized controlled study investigating the effect of nafamostat mesilate on mortality,
CRRT filter life span and adverse events in patients with bleeding tendency. Seventy-three Patients were randomized into
either the futhan or no-anticoagulation group. Thirty-six subjects in the futhan group received nafamostat mesilate, while
thirty seven subjects in the no-anticoagulation group received no anticoagulants. Baseline characteristics and appropriate
laboratory tests were taken from each group. The mortality between the two groups was not significantly different.
Nevertheless, between the futhan group and the no-anticoagulation group, the overall number of filters used during CRRT
(2.7162.12 vs. 4.5063.25; p = 0.042) and the number of filters changed due to clots per 24 hours (1.1560.81 vs. 1.7461.62;
p= 0.040) were significantly different. When filter life span was subdivided into below and over 12 hours, the number of
filters functioning over 12 hours was significantly higher in the futhan group than in the no-anticoagulation group
(p = 0.037, odds ratio 1.84). There were no significant differences in transfusion, mortality, or survival between the two
groups, and no adverse events related to nafamostat mesilate were noted. Hence, nafamostat mesilate may be used as an
effective and safe anticoagulant, without increasing the risk of major bleeding complications, in patients prone to bleeding.
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Introduction
Continuous renal replacement therapy (CRRT) is an
effective renal replacement modality used to manage hemo-
dynamically unstable patients with deteriorated renal function
[1]. In CRRT, anticoagulants are generally used to prevent
circuit coagulation, and heparin is used most commonly, in this
regard. However, there are risks associated with the use of
heparin as an anticoagulant in patients at high risk of bleeding.
Thus, modified anticoagulation methods, such as low dose
heparin, low molecular weight heparin, regional citrate,
regional unfractionated heparin, thrombin antagonists, and
prostacyclin anticoagulation, are used to ensure filter patency
and patient safety in these patients despite their limitations and
adverse events [2–7]. Nafomostat mesilate (6-amno-2-naphthyl
p-guanidinobenzoate dimethane sulfonate; Futhan, SK chem-
icals, Seoul, Republic of Korea) is a prostacyclin analog that
inhibits serine proteases and is rapidly eliminated from blood
with a half-life of 8 minutes. The extremely short half-life
makes it a suitable substitute for heparin in patients with a high
tendency for bleeding [8–10]. Even though a few retrospective
studies have shown that nafamostat mesilate is effective in
CRRT among patients at high risk of bleeding [11–13], no
prospective study has evaluated the effect of nafamostat
mesilate under controlled conditions. Accordingly, to elucidate
the efficacy and safety of nafamostat mesilate, we performed a
single center, randomized, controlled study in CRRT patients
with high risk of bleeding.
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Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Patients and study design
In this unblinded, single center, randomized, prospective
controlled study, 73 patients (18–80 years old) who were admitted
to the intensive care unit (ICU) for CRRT with hemorrhagic
tendency were enrolled from September 2007 to August 2010 at
Severance Hospital, Seoul, Republic of Korea. Patients were
included if they required CRRT and had at least one of the
following hemorrhagic tendencies: (1) platelet count ,100,000/
mL, (2) activated partial thromboplastin time.60 seconds, (3)
prothrombin time-international normalized ratio.2.0, (4) active
hemorrhage, (5) surgery within the past 48 hours, (6) cerebral
hemorrhage within the past 3 months or history of a major
cerebral bleeding, and (7) septic shock or disseminated intravas-
cular coagulation. Patients who were pregnant (or possibly
pregnant), breast feeding, allergic to nafamostat mesilate, or had
any other conditions that made the candidate unfit according to
the attending physician were excluded. The patients were followed
for 1 to 23 days until CRRT discontinuation. The Institutional
Review Board of Severance Hospital approved this study, and all
patients or their legal representative provided written informed
consent. Since the registration of the trial to a recognized
international registry was not mandatory during Institutional
Review Board approval, the registration was completed during the
study. The authors confirm that all ongoing and related trials for
this drug are registered.
Randomization and Treatment allocation
At enrollment, the patients were assigned randomly with
stratification of diabetes mellitus. The patients who fulfilled the
inclusion criteria and none of the exclusion criteria were assigned
to either the futhan group or no-anticoagulation group according
to the random assignment number by preformed random place
card.
Outcomes
The primary outcome of this study was to assess the mortality of
the futhan group and compare it to the mortality of the no-
anticoagulation group. The secondary outcome was to evaluate
filter life span (overall filter, filter containing clot at exchange, filter
changed due to clotting), transfusion, and adverse events.
Covariates
Vital signs including pulse rate and blood pressure were checked
when CRRT was initiated. Data on patient demographics and
underlying diseases were collected at screening. In addition,
laboratory examinations including hematologic, biochemical, and
coagulation tests were done at screening and at the cessation of
CRRT. If patients died during CRRT, the last examination before
death was used. Overall mortality, mortality during hospitaliza-
tion, and mortality 28 days after CRRT were compared between
groups to evaluate the safety of nafamostat mesilate.
Filter life span using the filter patency time and the reason for
filter failure (e.g., filter clot, ultrafiltrate loss ,150 mL/hr within
3 hours, persistent transmembrane pressure higher than
200 mmHg, or an extracorporeal circuit abnormality due to
another apparatus [such as radiologic examination], etc.) were
evaluated. When CRRT was discontinued, the average life span of
the filter was calculated. If the last filter was discontinued due to
death or the discretion of the clinician, it was excluded from
analysis to derive a more exact life span of CRRT filters.
CRRT Setting
Central venous access was achieved by placing a double lumen
catheter into the internal jugular or femoral veins. CRRT was
conducted using Prisma (Gambro, Lund, Sweden) or Prismaflex
(Gambro). A commercially prepared bicarbonate-buffered re-
placement fluid (Hemosol B0, Gambro) was used as a dialysate
and replacement fluid. Blood flow was set between 130 mL/min
and 200 mL/min, and ultrafiltration rates were at least 35 mL/
(hr?kg). Replacement fluid was delivered by the predilution mode.
Filters were electively exchanged every 48 hours, if they were not
discontinued due to malfunction of the filter due to various
reasons, death, or at the request of the physician.
The initial dose of nafamostat mesilate was 20 mg/hr. The
dosage was adjusted from 10 mg/hr to 30 mg/hr according to
each patient’s status. For priming, two vials of nafamostat mesilate
were dissolved in 2 mL of 5% glucose fluid and mixed with
1000 mL of normal saline. After carefully removing air bubbles
from the circuit with the prepared fluid, nafamostat mesilate was
dissolved with 15 mL of 5% glucose fluid and loaded into the
anticoagulation line with a starting dose of 20 mg/hr. The
nafamostat mesilate was administered throughout the CRRT
duration in futhan group.
In the no-anticoagulation group, no placebo medication was
administered.
Transfusion
Packed red blood cells were transfused when hemoglobin level
decreased below 7 g/dL or below 10 g/dL with evidence of acute
bleeding. Platelet concentrates are transfused when the platelet
level decreased below 20,000/mL or 50,000/mL with evidence of
acute bleeding. Fresh frozen plasma was transfused when
prothrombin time fell below 70% with evidence of bleeding or if
disseminated intravascular coagulation was suspected.
Adverse events
Physical examination was performed to collect data on allergies
and cardiovascular, pulmonary, gastrointestinal, hepatobiliary,
endocrinologic, nephrologic, urologic, muscular, neurologic, and
psychiatric backgrounds at the screening before beginning the
CRRT and after CRRT by the same researcher. Adverse events
were categorized using the World Health Organization Adverse
Reaction Terminology (WHO-ART) [14]. The severity of the
adverse events was categorized using The Common Terminology
Criteria for Adverse Events (CTCAE) [15]. Relations between
adverse events and medications were categorized as (1) definitely
related, (2) probably related, (3) possibly related, (4) probably not
related, and (5) definitely not related.
Statistics
All variables were analyzed using SPSS for Windows version
18.0 (SPSS, Inc., Chicago, IL, USA). Data are expressed as means
6 standard deviation. Comparisons between the futhan group and
no-anticoagulation group were conducted using Student’s t-tests.
Chi-square tests were used to compare frequency measurements
between the two groups. Logistic regression analyses were used to
compare the statistical significance of each category within adverse
events. Kaplan-Meyer estimator was used in survival curve. The
comparison between survival curves were performed by log-rank
test. All p-value less than 0.05 were considered statistically
significant.
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Sample size calculation was performed using GPower version
3.01. Considering previous study, we hypothesized that the rate of
primary outcome would be 50% in patients undergoing CRRT
[1,4,5]. A priori power calculations estimated that a minimum of
31 subjects in each arm would enable us to detect 15% allowable
error in mortality (alpha = 0.01). Considering a 5% drop-out rate
during the study, 31 subjects were determined to be sufficient.
Results
Baseline characteristics
Out of the 73 enrolled patients, 60 patients completed the study;
four patients from the futhan group, and nine patients from the
no-anticoagulation group were dropped out. Reasons for drop out
are shown in Figure 1, such as prescribing drugs that would
compromise the study, adverse events, etc. Thus, the final number
of patients in the futhan group and the no-anticoagulation group
were 32 and 28, respectively. At the start of CRRT, no significant
differences between groups according to age, sex, vital signs,
laboratory tests, or acute kidney injury when stratified by RIFLE
criteria, APACHE II score, and the Cleveland Clinical Founda-
tion Score were found (Table 1). There was no significant
difference between groups in laboratory test at the cessation of
CRRT (Table not included).
Mortality
Although the overall mortality was higher than expected, both
groups showed similar overall mortality (futhan: 75.00%, n= 24
vs. no-anticoagulation: 74.07%, n= 20; p=0.927). When patients
were stratified by prevalence of diabetes mellitus or their
APACHE II score, no significant difference between the groups
was found; however, diabetic patients showed higher mortality
than that in non-diabetic patients. Mortality during hospitalization
was similar between the groups (futhan: 71.88%, n= 23 vs. no-
anticoagulation: 74.07%, n= 20; p=0.963). Also, mortality on 28
days after applying CRRT was not significantly different between
the two groups (futhan: 75.00%, n= 24 vs. no-anticoagulation:
74.07%, n= 20; p=0.927) (Table 2). Median survival in the
futhan group and no-anticoagulation group was 3.96 and 4.42
days, respectively (p=0.680) (Figure 2). There were no significant
differences in median survival between the two groups, when we
stratified overall mortality according to prevalence of diabetes,
RIFLE criteria, and APACHE II scores (data not shown).
Filter life span
The only significant change between the futhan and no-
anticoagulation group was found in the overall number of filters
changed during CRRT and the number of filters changed due to
clots per 24 hours. Filter life span tended to be longer in the futhan
group than in the no-anticoagulation group, although without
Figure 1. Enrollment, randomization, and follow up. Out of 162 patients who were eligible to the study, 73 patients were enrolled in the study,
and 60 patients completed the study for analysis.
doi:10.1371/journal.pone.0108737.g001
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statistical significance. Also, the number of filters used during
CRRT tended to be higher in the no-anticoagulation group than
the futhan group, without statistical significance (Table 3).
Interestingly, when filter life span was subdivided into below and
over 12 hours, the number of filters functioning over 12 hours was
significantly higher in the futhan group than the no-anticoagula-
tion group. Hence, we can assume that filters are likely to be
functional for a longer time in the futhan group than in the no-
anticoagulation group (Table 4).
Transfusion
The number of platelet concentrate transfusions was signifi-
cantly lower in the futhan group than the no-anticoagulation
group. However, there was no significant difference in the number
of packed red blood cells and fresh frozen plasma transfusions
between the two groups (Table 5).
Adverse events
There were 52 adverse events from 33 patients in the futhan
group and 59 events from 33 patients in the no-anticoagulation
group (p=0.133). In the futhan group, there were 4 cardiologic
events, 11 pulmonary events, 9 gastrointestinal events, 2 hema-
Table 1. Baseline characteristics.
Characteristics Futhan group No-anticoagulation group P value
(n =36) (n =37)
Demographics
Age (years) 52.97613.94 57.54613.04 0.152
Male, N (%) 24 (66.67%) 20 (54.05%) 0.271
Underlying disease, N(%)
Hypertension 14 (38.9%) 13 (36.1%) 0.808
Diabetes mellitus 13 (36.1%) 8 (22.2%) 0.195
Vital signs
SBP (mmHg) 122.42620.89 121.03621.33 0.779
DBP (mmHg) 66.75615.39 63.68612.44 0.350
Pulse rate (bpm) 113.36624.27 113.35623.10 0.999
Body temperature (uC) 36.6860.81 36.8161.14 0.585
RR (/min) 19.7164.58 20.0564.62 0.755
Laboratory tests at start of CRRT
WBC (6103/m‘) 12.45611.11 10.4969.88 0.427
Hb (g/dL) 8.4961.55 9.0761.86 0.147
Platelet (6103/m‘) 57.44640.05 90.92697.39 0.087
ESR (mm/hr) 22.70625.34 26.67634.52 0.920
Uric acid (mg/dL) 7.4762.93 7.0562.58 0.224
BUN (mg/dL) 64.09625.64 61.71630.16 0.385
Cr (mg/dL) 3.0961.09 3.4161.96 0.718
Na (mmol/L) 140.2868.00 140.8167.49 0.774
K (mmol/L) 4.1960.82 4.2461.06 0.843
Total CO2 (mmol/L) 20.6366.21 21.2264.96 0.288
Patient severity index at screening.
RIFLE criteria
Risk 4 (11.1%) 9 (24.30%) 0.140
Injury 10 (27.8%) 8 (21.6%) 0.542
Failure 22 (61.1%) 18 (51.3%) 0.285
Loss and ESRD 0 1 (2.7%) 0.493
Total APACHE II score 26.7265.26 26.8466.00 0.931
Cleveland clinical foundation score 17.31611.11 13.7363.25 0.071
doi:10.1371/journal.pone.0108737.t001
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tologic events, 2 nephrologic events, 1 gynecologic event, 3
neurologic events, 2 dermatologic events, and 20 infectious events.
There were five adverse events which were related to bleeding in
the futhan group. The bleeding consisted of one grade 1
pulmonary hemorrhage, one grade 4 gastrointestinal bleeding,
two grade 2 gastrointestinal bleedings, and one grade 1 vaginal
bleeding. However, there were no adverse events related to
nafamostat mesilate. Pulmonary hemorrhage resulted from
cardiopulmonary resuscitation, and vaginal bleeding was due to
dysfunctional uterine bleeding which was resolved with medrox-
yprogesterone. Out of three gastrointestinal bleedings, one severe
incidence was due to thrombocytopenia by allopurinol, while the
other two incidences were due to ulcer and resolved by transfusion
and medication. Out of 59 adverse events in the no-anticoagu-
lation group, there were 7 cardiologic events, 9 pulmonary events,
2 hepato-biliary events, 8 gastrointestinal events, 7 hematologic
events, 2 endocrinologic events, 1 gynecologic event, 1 neurologic
event, 2 dermatologic events, and 20 infectious events. There were
also five adverse events that were related to bleeding in the no-
anticoagulation group. The adverse events included a variceal
bleeding, two grade 2 events of gastrointestinal bleeding, one
grade 1 gastrointestinal bleeding, and one catheter insertion site
oozing. Logistic regression analysis of the frequency of each
adverse event showed no statistical difference between the two
groups.
Discussion
Nafamostat mesilate is a synthetic serine protease inhibitor
originally developed as a therapy for pancreatitis. However, due to
its inhibitory function on platelet aggregation and coagulation
factors, such as thrombin, Xa, XIIa, kallikrein, and complement
system components, nafamostat mesilate has been used more
commonly since 1990 (mainly in Japan) as an anticoagulant in
CRRT. There are no absolute contraindications in using
nafamostat mesilate as an anticoagulant in patients who are
planning to receive CRRT. This is a strong advantage for
nafamostat mesilate, compared to the characteristic side effects
and contraindications of other anticoagulants. However, nafamo-
stat mesilate is not accepted as a standard anticoagulant for CRRT
due to limited evidence [16–18].
In this study, we evaluated the effect of nafamostat mesilate as
an anticoagulant with a randomized, prospective, controlled study
protocol. The mortality rate in our study was significantly higher
compared to others with similar APACHE II score. This is
probably due to the fact that the subjects enrolled in our study
comprised a bleeding tendency with needs for CRRT, which
would add more severity, when compared to other subjects with
the same APACHE II score. Nevertheless, overall mortality,
mortality during hospitalization, mortality at 28 days, and median
survival were not statistically different between the two groups,
despite concerns for severe bleeding in the futhan group. Although
Figure 2. Survival curve of the Futhan group and No-anticoagulation group.
doi:10.1371/journal.pone.0108737.g002
Table 2. Comparison of mortality in each group.
Mortality Futhan group No-anticoagulation group P value
Overall mortality 24 (75.00%) 20 (74.07%) 0.927
Mortality on 28 days 23 (71.88%) 20 (74.07%) 0.963
Mortality within hospital 24 (75.00%) 20 (74.07%) 0.927
doi:10.1371/journal.pone.0108737.t002
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the overall number of filters changed within 24 hours was not
significantly different, comparison of the number of filters changed
due to clotting per 24 hours showed that the futhan group
required significantly fewer filters than the no-anticoagulation
group did. Also, when the groups were subdivided according to
filter life span over and below 12 hours, significantly more filters
were maintained over 12 hours in the futhan group than the no-
anticoagulation group. CRRT is a labor intensive procedure
requiring constant attention by health care providers, and our
results suggest that nafamostat mesilate can reduce the workload of
health care providers, cost, and eventually improve patient
outcomes by reducing the time spent preparing CRRT due to
recurrent filter failure.
Currently, regional citrate anticoagulation is recommended in
the 2012 Kidney Disease Improving Global Outcome (KDIGO)
Clinical Practice Guidelines for Acute kidney Injury for patients
with bleeding tendencies [19]. This conclusion was drawn from
several clinical studies showing the advantages of citrate in
comparison to heparin in terms of prolonged filter life span,
reduced hemorrhagic incidence, and lower transfusion require-
ment [20–25]. However, since citrate is metabolized by the liver,
citrate is applied cautiously in patients with severe liver failure,
septic or cardiogenic shock, and impaired citrate metabolism. But,
the patients who are planned to undergo CRRT, will most likely
have decreased liver or cardiac function, sepsis, or conditions that
can lead to impaired citrate metabolism. As a result, there is the
possibility for acid-base imbalance, electrolyte abnormalities,
hypotension and arrhythmia, which can be life-threatening by
itself, but would not be a concern in nafamostat mesilate [26,27].
Since it is recommended to change CRRT filters in at least every
72 hours, filters were changed every 48 hours in the present study,
even though the filter was not clotted. Hence, overall filter life span
in the present study was shorter than other studies performed with
citrate, in which the median filter life span was about 120 hours. If
we were to use citrate in our clinical setting, the filter life span
would not be as long as 120 hours and probably would be similar
to the filter life span that we observed in the futhan group. Hence,
further studies are required to compare the clinical advantages
between citrate and nafamostat mesilate.
The transfusion of packed red blood cells and fresh frozen
plasma during CRRT was not significantly different between the
two groups. This result indicates that bleeding risk due to
nafamostat mesilate may be negligible. However, a significantly
smaller amount of platelet concentrates transfusion was required
in the futhan group, and this might have resulted from higher
platelet consumption in the no-anticoagulation group, which was
due to filter clotting.
There have been several reports of circuit clotting and adverse
events, including anaphylaxis, agranulocytosis, and hyperkalemia
with nafamostat mesilate [28–31]. Hence, we investigated adverse
events in the present study. Two patients dropped out from the
study in the futhan group due to adverse events that led to
Table 3. Distribution of filter life spans in each group.
Futhan group No-anticoagulation group Total
#12 hrs 57 (41.3%) 26 (27.7%) 83 (35.8%)
.12 hrs 81 (58.7%) 68 (72.3%) 62 (64.2%)
Total 138 94 232
P = 0.037; odd ratio 1.840.
doi:10.1371/journal.pone.0108737.t003
Table 4. Comparison of filters consumed in each group.
Futhan group No-anticoagulation group P value
Filter life span (hours)
Overall filters 26.63621.14 22.70620.67 0.160
Filters with clots 26.03620.27 21.25619.49 0.106
Filters changed due to clots 27.05620.29 23.23619.61 0.221
Number of filters used in the ICU
Overall filters 2.7162.12 4.5063.25 0.042
Filters with clots 86.2% 77.7% 0.111
Filters changed due to clots 73.4% 72.5% 1.000
Number of filters/24 hours
Overall filters 1.6061.67 1.9061.60 0.383
Filters with clots 1.4561.57 1.8561.62 0.378
Filters changed due to clots 1.1560.81 1.7461.62 0.040
doi:10.1371/journal.pone.0108737.t004
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discontinuation of nafamostat mesilate. The events were severe
hyperbilirubinemia (grade 3) and moderately elevated prothrom-
bin time (grade 2) that were ‘‘definitely’’ not related to treatment
with nafamostat mesilate. There were no bleeding adverse events
related to nafamostat mesilate. The 52 adverse events observed in
the futhan group during the study were also ‘‘definitely’’ not
related to nafamostat mesilate, except for one incidence of
gastrointestinal bleeding that was ‘‘probably’’ not related to the
medication. The comparison of the frequency of each adverse
event indicated that nafamostat mesilate is as safe as no-
anticoagulation treatment.
Limitations
The limitation of this study was a higher drop-out rate than
expected. A priori power analysis showed 31 subjects in each arm
to be sufficient to detect a meaningful difference in mortality.
Considering 5% drop-out rate, 33 patients in each arm were
considered sufficient for the study. However, during the study, a
large number of patients than expected dropped out in the no-
anticoagulation group, despite the fact that we have enrolled 36
subjects in the futhan group and 37 subjects in the no-
anticoagulation group. The final number of patients in the no-
anticoagulation group was 28, while that in the futhan group was
32. However, although the number of subject was insufficient,
there have been statistically significant advantages in filter patency.
Hence, further study, preferably a multi-centered study, might
reveal more noticeable advantages for using nafamostat mesilate in
CRRT patients with bleeding tendencies.
Conclusions
This prospective, randomized, controlled study confirmed that
nafamostat mesilate prolongs filter life span without any added
adverse events. These results suggest that nafamostat mesilate is a
safe and effective anticoagulant in CRRT patients at high risk of
bleeding.
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